p53 Status Identifies Two Subgroups of Triple-negative Breast Cancers with Distinct Biological Features
Authors:
- Elia BiganzoliEBElia Biganzoli
- Danila CoradiniDCDanila Coradini
- Federico AmbrogiFAFederico Ambrogi
- Jonhatan M. GaribaldiJGJonhatan M. Garibaldi
- Daniele SoriaDSDaniele Soria
- Andrew R. GreenAndrew R. Green
- Massimo PedrialiMPMassimo Pedriali
- Mauro PiantelliMPMauro Piantelli
- Patrizia QuerzoliPQPatrizia Querzoli
- Patrizia BoracchiPBPatrizia Boracchi
Open Access
- 2 January 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 41 (2) , 172-179
Abstract
Despite the clinical similarities triple-negative and basal-like breast cancer are not synonymous. Indeed, not all basal-like cancers are negative for estrogen receptor, progesterone receptor and HER2 expression while triple-negative also encompasses other cancer types. P53 protein appears heterogeneously expressed in triple-negative breast cancers, suggesting that it may be associated with specific biological subgroups with a different outcome. We comparatively analyzed p53 expression in triple-negative tumors from two independent breast cancer case series (633 cases from the University of Ferrara and 1076 cases from the University of Nottingham). In both case series, p53 protein expression was able to subdivide the triple-negative cases into two distinct subsets consistent with a different outcome. In fact, triple-negative patients with a p53 expressing tumor showed worse overall and event-free survival. The immunohistochemical evaluation of p53 expression may help in taming the currently stormy relationship between pathological (triple-negative tumors) and biological (basal breast cancers) classifications and in selecting patient subgroups with different biological features providing a potentially powerful prognostic contribution in triple-negative breast cancers.Keywords
This publication has 29 references indexed in Scilit:
- Genetic Susceptibility Loci for Breast Cancer by Estrogen Receptor StatusClinical Cancer Research, 2008
- Use of immunohistochemical markers can refine prognosis in triple negative breast cancerBMC Cancer, 2007
- TP53mutation status and gene expression profiles are powerful prognostic markers of breast cancerBreast Cancer Research, 2007
- The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer SubtypesClinical Cancer Research, 2007
- Prognostic markers in triple‐negative breast cancerCancer, 2006
- Molecular Classification and Molecular Forecasting of Breast Cancer: Ready for Clinical Application?Journal of Clinical Oncology, 2005
- High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analysesInternational Journal of Cancer, 2005
- Breast cancer classification and prognosis based on gene expression profiles from a population-based studyProceedings of the National Academy of Sciences, 2003
- Repeated observation of breast tumor subtypes in independent gene expression data setsProceedings of the National Academy of Sciences, 2003
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences, 2001